Sparingvision

Developer of drugs using gene therapy to treat retinitis pigmentosa

placeParis, Ile De France, France calendar_todayFounded 2016 groups41 employees language sparingvision.com

Registered entities

Innovation

6 patent families (2 granted) — focus: Chemistry & metallurgy, Human necessities; filing pace accelerating. Cited 366 times.

YearFilings
20191
20201
20222
20233
20245
20253
20262

Social engagement

Social engagement: 7.1K social following, 10 posts in the last 12 months — below the industry typical range.

Investor mix

12 investors on record; lead investors include Jeito, UPMC Enterprises, 4Bio Capital, UPMC.

Investor typeCountShare
Venture capital542%
Accelerator & incubator217%
Bank & private debt18%
Other / undisclosed433%

Recent activity

1 Jul 2026
Event
SpartingVision 2026
18 Jun 2026
Milestone
regulatory
16 Jun 2026
Recognition
Coming soon